Why that happens is less clear though. Is it a fault of mRNA tech itself? Or the dosing schedule? 21 days is very close together for a 2 dose vaccine, most are 6 months or years apart.
Using 21 days was a good way to get the trials done fast, if they'd used 6 months we'd be where we were 5 months ago, but this was one of the risks. Canada, which spaced doses out further, isn't seeing nearly as high of a rate of breakthrough cases.
I'm not saying we can conclude definitely that dosing is the problem, but it's a question worth investigating before coming to any firm conclusions that mRNA vaccines aren't good enough.